Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Simcere Pharmaceutical Group Ltd
HKEX:2096

Watchlist Manager
Simcere Pharmaceutical Group Ltd Logo
Simcere Pharmaceutical Group Ltd
HKEX:2096
Watchlist
Price: 11.42 HKD 0.53% Market Closed
Market Cap: HK$29.6B
Write Note Create Alert Ask AI

Intrinsic Value

The intrinsic value of one Simcere Pharmaceutical Group Ltd stock under the Base Case scenario is 10.42 HKD. Compared to the current market price of 11.42 HKD, Simcere Pharmaceutical Group Ltd is Overvalued by 9%.

Valuation Methods:
DCF Value
HK$11.79
Relative Value
HK$9.05
DCF Value
HK$11.79
Relative Value
HK$9.05
Intrinsic Value
10.42 HKD
Overvaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Simcere Pharmaceutical Group Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about Simcere Pharmaceutical Group Ltd?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is Simcere Pharmaceutical Group Ltd valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Simcere Pharmaceutical Group Ltd.

Explain Valuation
Compare Simcere Pharmaceutical Group Ltd to

Fundamental Analysis

Profitability Score
Profitability Due Diligence

Loading...
Loading...
Loading...
Loading...
profitability
Score

Solvency Score
Solvency Due Diligence

Loading...
Loading...
Loading...
Loading...
solvency
Score
Simcere Pharmaceutical Group Ltd
HKEX:2096
CN
Pharmaceuticals
Market Cap
29.6B HKD
IPO
Oct 27, 2020
CN
Pharmaceuticals
Market Cap
29.6B HKD
IPO
Oct 27, 2020
Price
HK$
¥
|
How do you feel about Simcere Pharmaceutical Group Ltd?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Simcere Pharmaceutical Group Ltd

Efficiency

Free Cash Flow Analysis
Simcere Pharmaceutical Group Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Wall St
Price Targets

Price Targets Summary
Simcere Pharmaceutical Group Ltd

Wall Street analysts forecast Simcere Pharmaceutical Group Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Simcere Pharmaceutical Group Ltd is 17.34 HKD with a low forecast of 12.42 HKD and a high forecast of 21.17 HKD.

Lowest Forecast
Wall Street Target
12.42 HKD
9% Upside
Average Forecast
Wall Street Target
17.34 HKD
52% Upside
Highest Forecast
Wall Street Target
21.17 HKD
85% Upside
Lowest
Price Target
12.42 HKD
9% Upside
Average
Price Target
17.34 HKD
52% Upside
Highest
Price Target
21.17 HKD
85% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
What is Dividend Safety Rate?
Shareholder Yield

Current shareholder yield for Simcere Pharmaceutical Group Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
= Dividend Yield
+ Buyback Yield
+ Debt Paydown Yield
Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is the Intrinsic Value of one Simcere Pharmaceutical Group Ltd stock?

The intrinsic value of one Simcere Pharmaceutical Group Ltd stock under the Base Case scenario is 10.42 HKD.

Is Simcere Pharmaceutical Group Ltd stock undervalued or overvalued?

Compared to the current market price of 11.42 HKD, Simcere Pharmaceutical Group Ltd is Overvalued by 9%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 315,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.